Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment.